Mylan Chairman Coury Handed More Central Role
Former Chairman Accelerates Into New Role Amid Coronavirus Challenge
Associated with Mylan since the mid-1990s and formerly serving as CEO for more than a decade, chairman Robert Coury has been appointed to a position of greater influence with the company, as Mylan fights battles on several fronts.
You may also be interested in...
Presenting its last ever financial earnings as a standalone company, Mylan revealed plans to host an Investor Day in the first quarter of next year to discuss the strategic direction of Viatris, Mylan’s proposed combination with Pfizer’s Upjohn which is due to close later this month.
Another regulatory approval for Mylan and Upjohn’s proposed combination into Viatris has been ticked off, with the Australian Competition and Consumer Commission saying it will not oppose the deal after Upjohn agreed to divestments to Aspen Pharmacare.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.